Last chance access: vatiquinone for mitochondrial disease patients
NCT ID NCT07159139
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This program offered vatiquinone, an experimental liquid medication, to patients with inherited mitochondrial diseases like Leigh syndrome who had already completed a previous safety study. The goal was to continue treatment for those who might benefit, but enrollment is now closed. It was not a cure, but aimed to help manage the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALPERS SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new oral drug help tame leigh syndrome?
- Worldwide data pool could pave the way for mitochondrial disease trials
- New study aims to unlock why infections hit mitochondrial disease patients hard
- New DNA test could end years of uncertainty for mitochondrial disease patients
- Could a common drug help kids with rare leigh syndrome?
- New drug aims to tame hard-to-control seizures in rare mitochondrial disorders